BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: QuietWon who wrote (38)	1/30/1999 4:48:00 PM
From: BRAVEHEART	Read Replies (2) of 423

Hi QuietWon, Ok I'll buy your argument on the P-3 theory. "50% of longer term biotech stock price run up occurs during the period from approval to enter phase III until time of marketing approval. IMCL awaiting approval to enter phase III - medical/testing part done, just waiting for the ok on the protocol / business plan, if you will. IMCL's own press release says to happen in 99Q1" I'll also go as far to support that argument that the technicals & fundamentals could support your argument assuming faviorable market conditions. clearstation.com biz.yahoo.com The stock has traded close to $14 as a annual high. If the product successfully advances into P-3 it would suggest that investors would be attracted to IMCL more than ever. The companies cash position is strong. Hence I would project a $15 share price by the Q following a FDA clearance to advance into P3 trials. This suggests a chance of at least 50% returns in a 6 month ( max ) time frame and passes the key goal of this thread. Funny I have followed both ONXX and VION. These head & Neck tumor companies must have an oath of tight lipp. Actually I found VION to be the most open. I targeted VION last spring when it was three. It traded to the resistance of it's warrents. Then recently the company delt with that situation. I predicted ( check my posts at Yahoo back to last spring ) it would break it's annual high because of this. It has been breaking out wildly ever since. clearstation.com My point is this. Have you checked and compared VION's H&N R&D and compared it to IMCL's I would be curious to see how the data stacks up. FINALLY as an investor I would like to know the safety and side effect profile of IMCL's H&N product. How did/does ONXX IMCL & VION stack up with their H&N results ??? BEST WISHES & THANKS FOR YOUR PLAUSIBLE FAVIORITE BIOTECH STOCK LONE WOLF

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next